Because the depletion of CMTM6 enhanced tumor-specific T cell responses by reducing PD-L1 expression (15), CMTM6 has gained attention not only as a key molecule involved in the PD-1/PD-L1 axis but also as a potential therapeutic target against cancers. This evidence concerns the gene CD274 and neoplasm.